Australian biotech market watch 22/01/10
Friday, 22 January, 2010
Health and biotech stocks have followed the All Ordinaries on a slide in morning trading on the back of a weak week in Wall St and concerns over the global economy. The All Ords are down 1.8% in early afternoon trading, with the S&P Health Care index experiencing a slight recovery from this morning, down only 0.25% as of 1pm.
One of the biggest drops was had by Mesoblast (ASX:MSB), which shed 18c to $1.95, although it's still up 44% over the past month.
Sirtex Medical (ASX:SRX) has also dropped 6%, down to $7.07, and Prima BioMed is back to 17c after bumping to 18c at yesterday's close.
pSivida (ASX:PVA) shed 23c, down to $4.05, and Patrys (ASX:PAB) has continued its decline of the past week, down 3.9% to 12.5c.
It wasn't all bad news, though. Cochlear (ASX:COH) managed to put on $1.69, to $66.12, in a strong morning's trading.
Xenotransplantation specialists, Living Cell Technology, has had some ups and downs over the past week, but recovered today to the tune of 2.4%, up to 21c.
CSL (ASX:CSL) was up slightly, adding 8c to $31.15, and ResMed (ASX:RMD) was steady.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
